可溶性环氧化物水解酶抑制剂TPPU治疗周围神经痛效果研究

›› 2019, Vol. 10 ›› Issue (3): 123-126.

可溶性环氧化物水解酶抑制剂TPPU治疗周围神经痛效果研究

张琳,张耀扬,白杰,王福

大连医科大学口腔医学院

收稿日期:2019-03-28 修回日期:2019-09-09 出版日期:2019-09-25 发布日期:2019-09-25
通讯作者: 王福 E-mail:fuwang@dmu.edu.cn
基金资助:
国家自然科学基金

Study of the effect of soluble epoxide hydrolase inhibitor TPPU in the treatment of peripheral neuralgia

Received:2019-03-28 Revised:2019-09-09 Online:2019-09-25 Published:2019-09-25
Supported by:
81771032

摘要/Abstract

摘要： 目的：探究可溶性环氧化物水解酶抑制剂1-（三氟甲氧基苯基）-3-（1-丙酰基哌啶-4-基）脲（TPPU）治疗周围神经痛效果。方法：选择SD大鼠，通过坐骨神经慢性压迫损伤建立坐骨神经痛模型。术前3 d至术后7 d给予（实验组）或不给予（对照组）TPPU灌胃处理。术后使用Von Frey测试SD大鼠痛阈，监测体质量变化，免疫组织化学染色观察神经新生血管数量及坐骨神经脊髓段尼氏小体表达。结果：实验组疼痛阈值和体质量增加明显高于对照组（P＜0.05）；免疫荧光结果显示实验组局部微循环改善，尼氏小体表达高于对照组（P＜0.05）。结论：TPPU可能通过改善微循环促进神经损伤修复，减少神经损伤性疼痛。

关键词: 环氧二十碳四烯酸, 环氧化物水解酶抑制剂, 1-（三氟甲氧基苯基）-3-（1-丙酰基哌啶-4-基）脲, 坐骨神经痛, 微循环

Abstract: Objective：To study the effects of soluble epoxide hydrolase inhibitor 1-(trifluoromethoxyphenyl)-3-(1-propionylpieridn--yl) urea (TPPU) on peripheral neuralgia by targeted blockade of soluble epoxide hydrolase.Methods：The chronic neuropathic pain were generated by chronic constriction injury of the sciatic nerve in SD rats. The rats were administrated with TPPU (experimental group) or without TPPU (control group) by gastric lavage daily 3 days before surgery to 7 days after surgery. The body weight and pain threshold (Von Frey assay)were measured. Immunohistochemical staining was used to observe the number of nerve neovascularization and the expression of Nissl bodies in the sacral part of the spinal cord.Results：Pain threshold and body weight gain in the experimental group were significantly higher than those in the control group (P＜0.05). Immunofluorescence results showed that the local microcirculation was improved in the TPPU-treated group, and the expression of Nissl bodies was higher than that in the control group (P＜0.05).Conclusions：TPPU targeted blockade of soluble epoxide hydrolasemay promote nerve damage repair and reduce nerve injury pain by improving the microcirculation

Key words: Epoxytetracosic acid , Soluble epoxide hydrolase inhibitor , 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea, Sciatica, Microcirculation

张琳张耀扬白杰王福. 可溶性环氧化物水解酶抑制剂TPPU治疗周围神经痛效果研究[J]. , 2019, 10(3): 123-126.

参考文献 24

[1]	Haanp?? M, Attal N, Backonja M, et al.NeuPSIG guidelines on neuropathic pain assessment[J].Pain, 2011, 152(1):14-27
[2]	Vallejo R, Tilley DM, Vogel L, et al.The role of glia and the immune system in the development and maintenance of neuropathic pain[J].Pain Prac, 2010, 10(3):167-184
[3]	Keilhoff G, Becker A, Kropf S, et al.Sciatic nerve ligation causes impairment of mitochondria associated with changes in distribution,respiration and cardiolipin composition in related spinal cord neurons in rats[J].Mol Cell Biochem, 2016, 421(1/2):41-54
[4]	Panigrahy D, Kalish BT, Huang S, et al.Epoxyeicosanoids promote organ and tissue regeneration[J].Proc Natl Acad Sci U S A, 2013, 110(33):13528-13533
[5]	Bellien J, Joannides R.Epoxyeicosatrienoic acid pathway in human health and diseases[J].J Cardiovasc Pharmacol, 2013, 61(3):188-196
[6]	Zhou Y, Yang J, Sun GY, et al.Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice[J].Cell Tiss Res, 2016, 363(3):399-409
[7]	Ostermann AI, Herbers J, Willenberg I, et al.Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern[J].Prostaglandins Other Lipid Mediat, 2015, 121(Pt A):131-137
[8]	Bennett GJ, Xie YK.A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man[J].Pain, 1988, 33(1):87-107
[9]	王红，冯泽国，徐龙河，等.坐骨神经慢性挤压伤模型大鼠行为学及形态学变化[J].中国组织工程研究与临床康复, 2007, 11(23):4590-4593
[10]	Zeldin DC.Epoxygenase pathways of arachidonic acid metabolism[J].J Biol Chem, 2001, 276(39):36059-36062
[11]	Spector AA, Fang X, Snyder GD, et al.Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function[J].Prog Lipid Res, 2004, 43(1):55-90
[12]	Pillarisetti S, Khanna I.Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors[J].Inflamm Allergy Drug Targets, 2012, 11(2):143-158
[13]	Panigrahy D, Edin ML, Lee CR, et al.Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice[J].J Clin Invest, 2012, 122(1):178-191
[14]	Inceoglu B, Schmelzer KB, Morisseau, et al.Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs)[J].Prostaglandins Other Lipid Mediat, 2007, 82(1/4):42-49
[15]	Spector AA.Arachidonic acid cytochrome P450 epoxygenase pathway[J].J Lipid Res, 2009, 50 Suppl:S52-S56
[16]	Abdu E, Bruun DA, Yang D, et al.Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures[J].J Neurochem, 2011, 117(4):632-642
[17]	Chen X, Chen X, Huang X, et al.Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury[J].Mol Neurobiol, 2016, 53(3):1565-1578
[18]	Wang L, Chen M, Yuan L, et al.14,15-EET promotes mitochondrial biogenesis and protects cortical neurons against oxygen/glucose deprivation-induced apoptosis[J].Biochem Biophys Res Commun, 2014, 450(1):604-609
[19]	Li R, Xu X, Chen C, et al.Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice[J].Prostaglandins Other Lipid Mediat, 2012, 99(3/4):68-78
[20]	Inceoglu B, Jinks SL, Ulu A, et al.Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways[J].Proc Natl Acad Sci U S A, 2008, 105(48):18901-18906
[21]	Brenneis C, Sisignano M, Coste O, et al.Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation[J].Mol Pain, 2011, 7:78-
[22]	Pillarisetti S, Khanna I.A multimodal disease modifying approach to treat neuropathic pain--inhibition of soluble epoxide hydrolase (sEH)[J].Drug Discov Today, 2015, 20(11):1382-1390
[23]	Imig JD, Hammock BD.Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases[J].Nat Rev Drug Discov, 2009, 8(10):794-805
[24]	Schmelzer KR, Kubala L, Newman JW, et al.Soluble epoxide hydrolase is a therapeutic target for acute inflammation[J].Proc Natl Acad Sci U S A, 2005, 102(28):9772-9777